Abstract
Purpose
Methods
Results
Conclusion
Figures and Tables
Fig. 1
MFI of GMT against each influenza antigen. Abbreviations : MFI, mean fold increase; GMT, geometric mean titer.
![kjpid-19-1-g001](/upload/SynapseData/ArticleImage/0153kjpid/kjpid-19-1-g001.jpg)
Fig. 2
MFI of GMT against each influenza antigen according to different immune state. (A) MFI of GMT against H1N1 antigen according to ALC count (MFI; ALC≤500/µL: 0.70, ALC >500/µL: 0.94). (B) MFI of GMT against H1N1 antigen according to WBC count (MFI; WBC ≤3,000/µL: 0.66, WBC >3,000/µL: 0.96). (C) MFI of GMT against H3N2 antigen according to ALC count (MFI; ALC ≤500/µL :0.71, ALC >500/µL: 1.30). (D) MFI of GMT against H3N2 antigen according to WBC count (MFI; WBC ≤3,000/µL: 0.87, WBC >3,000/µL: 1.27). (E) MFI of GMT against B antigen according to ALC count (MFI; ALC ≤500/µL: 1.00, ALC >500/µL: 2.09). (F) MFI of GMT against B antigen according to WBC count (MFI; WBC ≤3,000/µL: 1.00, WBC >3,000/µL: 2.14). Abbreviations:MFI, mean fold increase; GMT, geometric mean titer; ALC, absolute lymphocyte count.
![kjpid-19-1-g002](/upload/SynapseData/ArticleImage/0153kjpid/kjpid-19-1-g002.jpg)
Table 1
Patients Characteristics
![kjpid-19-1-i001](/upload/SynapseData/ArticleImage/0153kjpid/kjpid-19-1-i001.jpg)
*two drugs: cisplatin and adriamycin
†three drugs: ifosfamide, adriamycin and etoposide or ifosfamide, adriamycin and dacarbazine
‡recurrence: cyclophosphamide and topotecan
∫ALL protocol: prednisolone, vincristine, daunorubicin, L-asparaginase, cytarabine and methotrexate
∥HDCT: carboplatin, thiotepa and etoposide or ifosfamide, cyclophosphamide and etoposide
Abbreviation: ALL, acute lymphoblastic leukemia
Table 2
Immunogenicity against H1N1
![kjpid-19-1-i002](/upload/SynapseData/ArticleImage/0153kjpid/kjpid-19-1-i002.jpg)
*two drugs : cisplatin and adriamycin
†three drugs : ifosfamide, adriamycin and etoposide or ifosfamide, adriamycin and dacarbazine
‡recurrence : cyclophosphamide and topotecan
∫ALL protocol : prednisolone, vincristine, daunorubicin, L-asparaginase, cytarabine and methotrexate
∥HDCT : carboplatin, thiotepa and etoposide or ifosfamide, cyclophosphamide and etoposide
Abbreviations : ALL, acute lymphoblastic leukemia; HDCT, high dose chemotherapy; ALC, absolute lymphocyte count
Table 3
Immunogenicity against H3N2
![kjpid-19-1-i003](/upload/SynapseData/ArticleImage/0153kjpid/kjpid-19-1-i003.jpg)
*two drugs : cisplatin and adriamycin
†three drugs : ifosfamide, adriamycin and etoposide or ifosfamide, adriamycin and dacarbazine
‡recurrence : cyclophosphamide and topotecan
∫ALL protocol : prednisolone, vincristine, daunorubicin, L-asparaginase, cytarabine and methotrexate
∥HDCT : carboplatin, thiotepa and etoposide or ifosfamide, cyclophosphamide and etoposide
Abbreviations) ALL; acute lymphoblastic leukemia, HDCT; high dose chemotherapy, ALC; absolute lymphocyte count
Table 4
Immunogenicity against B
![kjpid-19-1-i004](/upload/SynapseData/ArticleImage/0153kjpid/kjpid-19-1-i004.jpg)
*two drugs : cisplatin and adriamycin
†three drugs : ifosfamide, adriamycin and etoposide or ifosfamide, adriamycin and dacarbazine
‡recurrence : cyclophosphamide and topotecan
∫ALL protocol : prednisolone, vincristine, daunorubicin, L-asparaginase, cytarabine and methotrexate
∥HDCT : carboplatin, thiotepa and etoposide or ifosfamide, cyclophosphamide and etoposide
Abbreviations : ALL, acute lymphoblastic leukemia; HDCT, high dose chemotherapy; ALC; absolute lymphocyte count
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)